2013 Press Releases Communiqués de presse

November 26, 2013 26 November, 2013

Sernova Corp Engages Carson Seabolt and Network IR

September 25, 2013 25 September, 2013

World First - Sernova's Cell Pouch™ Shown to Provide a Safe Environment for Therapeutic Insulin Producing Islets in Humans with Type 1 Diabetes

September 10, 2013 10 September, 2013

Sernova Corp Engages Ray Matthews & Associates

September 9, 2013 9 September, 2013

Sernova And Medicyte To Collaborate On Cell-Based Therapy To Treat Haemophilia

September 3, 2013 3 September, 2013

Sernova to Present at 15th Annual Rodman & Renshaw Global Investment Conference

July 8, 2013 8 July, 2013

Sernova Receives Patent Allowance for Therapeutic Immune Privileged Cell Technologies

June 23, 2013 23 June, 2013

Sernova Receives Patent Allowance for Therapeutic Cell Immune Protection Technology

May 8, 2013 8 May, 2013

Sernova Provides Corporate Update and Results of 2013 Annual General Meeting

March 24, 2013 24 March, 2013

Sernova Awarded Funding to Optimize its Sertolin™ Local Therapeutic Cell Anti-Rejection Technology for the Treatment of Chronic Diseases

February 28, 2013 28 February, 2013

Sernova and Centre for Commercialization of Regenerative Medicine Partner To Treat Chronic Diseases

February 19, 2013 19 February, 2013

Sernova Completes Non-Brokered Private Placement

January 21, 2013 21 January, 2013

Sernova Announces Non-Brokered Private Placement

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 26, 2013 26 November, 2013

Sernova Corp Engages Carson Seabolt and Network IR


Source: Sernova Corp

November 27, 2013, 6:00 a.m. EDT

LONDON, ONTARIO (Marketwire – November 27, 2013) - Sernova Corp (TSX-V: SVA), today is pleased to announce it has engaged Carson Seabolt and Network IR (“Network”) to develop and execute a comprehensive investor communications program to raise awareness of the Company within North American and International investment communities.

“Carson Seabolt and his team at Network IR are well-respected and will assist in the capital and institutional markets as we approach important Company milestones including anticipated clinical trial results in 2014,” said Dr. Philip Toleikis, Sernova Corp Chief Executive Officer.

“Our team is very excited to begin working with Sernova and its Management. It is a very rare opportunity to find a clinical-stage company that is working towards building such a worthwhile and potentially game-changing portfolio of products. I feel strongly that Dr. Toleikis and the entire Sernova team have the ability to deliver to the market, future patients and society a better way of treating what were once considered lifelong illnesses,” said Andrew Mugridge of Network IR.

“There is a lot to like about Sernova at this exciting juncture, and CEO Philip Toleikis is committed to ensure Sernova’s story is told to an ever-discerning retail audience. Attracting Carson Seabolt and NIR is a testament to Dr. Toleikis’s intuitive understanding that capital markets require an engaging, supportive retail ecosystem in the fruition of great projects. I credit Philip’s commitment to his stakeholders as we march into a promising 2014,”said Ray Matthews, Strategic Advisor.

Under the terms of the Company's agreement with Network IR, the Company will pay to Network a cash fee of $6,000 per month for six months and grant to Network a total of 300,000 incentive stock options, each option being exercisable, once vested, into one common share of the Company at a purchase price of $0.15 per share. The options shall vest in four equal quarterly installments, and will be governed by the Company's option plan and the policies of the TSX Venture Exchange.

About Sernova Sernova Corp is a clinical stage company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases to replace proteins or hormones in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device which when placed under the skin forms an environment rich in tissue matrix and microvessels, ideal for placing therapeutic cells which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technology Sertolin(TM) which provides an immune-protected environment for the therapeutic cells.

About the Cell Pouch(TM) The Cell Pouch(TM) is a proprietary scalable medical device which has been contract manufactured (ISO13485) to meet international regulatory standards. It is placed under the skin, and forms an ideal environment rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type 1 diabetes receiving an islet transplant.

About Sertoli Cells Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting preclinical studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Clinical Islet Transplantation Program Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta.

About Network IR Network IR is one of Canada's premier full service investor relations companies. Network IR provides its client companies with exposure, presence and access to the heart of the public markets. To date, the Network team have assisted in raising over $100 Million in equity finance and have helped numerous client companies reach their development goals and significant market capitalization. For more information on Network IR, visit their corporate website at http://www.networkir.com/

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Ray Matthews and Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 www.raymatthews.ca 604.818.7778

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 25, 2013 25 September, 2013

World First - Sernova's Cell Pouch™ Shown to Provide a Safe Environment for Therapeutic Insulin Producing Islets in Humans with Type 1 Diabetes


Dr. James Shapiro, Principal Investigator, Presents Encouraging Results at the XIV World Congress of the International Pancreas and Islet Transplantation Association

LONDON, ONTARIO (Marketwire — September 26, 2013) - Sernova Corp (TSX-V: SVA), today announced that Dr. James Shapiro, principal investigator of the clinical study presented encouraging safety and biocompatibility results for the Cell Pouch(TM) and following islet transplant, proof of islet cell survival and the presence of insulin in the first two patients of an up to 20 patient study. The explanted Cell Pouch(TM) also showed no evidence of immune system attack of the islet cells. The results were presented in a podium session at the XIV World Congress of the International Pancreas and Islet Transplantation Association in Monterey California.

"We are really encouraged by the initial results of this ground-breaking study. The preliminary findings that human islets survive under the skin within the Cell Pouch pave the way for our ongoing studies in patients that will now test how effective this new approach will be," said Dr. James Shapiro. "Importantly, the islets were shown to be residing within a natural tissue matrix in the device, and were nicely integrated with microvessels, and stained for insulin, glucagon, somatostatin and polypeptide at the 30 day time point." Dr. Shapiro further stated, "We will now begin to assess both the longer-term safety and efficacy of islets placed in the Cell Pouch in patients with diabetes, and will follow them for up to three years. We look forward to presentation of additional results as the study progresses."

In this study, patient volunteers with insulin-dependent diabetes and hypoglycemia unawareness who are receiving an islet transplant following informed consent are being implanted with the Cell Pouch(TM) which is subsequently transplanted with human donor islets. To protect the islets from immune cell attack, the patients are given an antibody and immunosuppressive medications.

In an initial assessment, the Cell Pouches(TM) in these first two patients were shown to meet the primary endpoint of being safe after implantation and prior to transplantation. The Cell Pouches(TM) were then transplanted with human donor islets followed by removal up to 30 days post- transplantation and islet survival assessed. The Cell Pouches(TM) were prepared for comprehensive histological analysis and assessed by experts in an independent blinded analysis for key features including device biocompatibility, tissue and microvessel development into the device, islet survival and the presence of insulin, glucagon, somatostatin, and polypeptide as well as protection of islets from immune system attack.

"The findings in these initial patients parallel the results in Sernova's multiple small and large animal safety and efficacy studies of the Cell Pouch. These showed an exemplary safety profile, and that islets were well- vascularised with microvessels and produced insulin. In addition, the islet-rich Cell Pouches then went on to show long-term glucose control in the diabetic animals," said Dr. David White, Professor Emeritus and Chair of Sernova's Scientific Advisory Board.

"We see these initial findings, in humans as an important next step in confirming the utility of the Cell Pouch in the clinical setting as providing a safe environment for therapeutic cells. We look forward to further results in this study and are excited to continue working in clinical indications where therapeutic cells can improve the quality of life for patients not only with diabetes but for those with other chronic debilitating diseases," said Philip Toleikis, President and CEO, Sernova Corp.

Sernova is developing the Cell Pouch(TM) as an enabling platform to treat a variety of chronic debilitating diseases including diabetes and hemophilia (in collaboration with Medicyte GmbH) with immune-protected therapeutic cells and is currently evaluating the safety and efficacy of the Cell Pouch(TM) in human clinical trials for diabetes.

About Sernova

Sernova Corp is a clinical stage company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases to replace proteins or hormones in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device which when placed under the skin forms an environment rich in tissue matrix and microvessels, ideal for placing therapeutic cells which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary technology Sertolin(TM) which provides an immune-protected environment for the therapeutic cells.

About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable medical device which has been contract manufactured (ISO13485) to meet international regulatory standards. It is placed under the skin, and forms an ideal environment rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type 1 diabetes receiving an islet transplant.

About Sertoli Cells

Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting preclinical studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Clinical Islet Transplantation Program

Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 www.raymatthews.ca 604.818.7778

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 10, 2013 10 September, 2013

Sernova Corp Engages Ray Matthews & Associates


LONDON, ONTARIO (Marketwire - September 11, 2013) - Sernova Corp. (TSX-V: SVA), is pleased to announce that it is has engaged Ray Matthews & Associates Inc. ('RM&A') to provide capital markets and advisory services, including investor relations activities.

"Ray Matthews and his team have a proven track record in providing strategic counsel for emerging growth companies," stated Dr. Philip Toleikis, President and CEO of Sernova Corp. "Ray Matthews and Associates joins Sernova at an exciting time with the Company focused on partnering and monetizing our pipeline. Our Company will benefit from RM&A's broad range of experience in strategic planning, corporate development, investor relations and operational consultation," Dr. Toleikis added.

"Sernova has a pipeline and IP portfolio which has the potential to achieve substantial shareholder value. I am excited to be able to add value and help attract additional talent and networks to help Sernova achieve its full potential," commented Ray Matthews.

Among other things, RM&A will facilitate communications between the Company and its shareholders and prospective investors and implement programs to raise awareness of the Company's business among prospective investors and the investment community. For more information on RM&A Inc., please visit www.raymatthews.ca.

Under the terms of the Company's agreement with RM&A, the Company will pay to RM&A a cash fee of $4,750 per month for six months and grant to RM&A a total of 160,000 incentive stock options, each option being exercisable, once vested, into one common share of the Company at a purchase price of $0.15 per share. The options shall vest in four equal quarterly installments, with the first 45,000 options vesting on December 5, 2013, and will be governed by the Company's option plan and the policies of the TSX Venture Exchange.

About Sernova

Sernova Corp is a clinical stage company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases to replace proteins or hormones in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device which when placed under the skin forms an environment rich in tissue matrix and microvessels, ideal for placing therapeutic cells which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary technology Sertolin(TM) which provides an immune-protected environment for the therapeutic cells.

About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable medical device which has been contract manufactured (ISO13485). It is placed under the skin, and forms an ideal environment rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type 1 diabetes receiving an islet transplant.

About Sertoli Cells

Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com



Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 www.raymatthews.ca 604.818.7778

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 09, 2013 9 September, 2013

Sernova And Medicyte To Collaborate On Cell-Based Therapy To Treat Haemophilia


* Novel Approach to Address Unmet Need for an Effective Therapy *

LONDON, ONTARIO and HEIDELBERG, GERMANY-- (Marketwire -- September 10, 2013) - Sernova Corp. (TSX- V: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte® cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.

The two companies have also entered into a nonbinding term sheet outlining the general terms of a collaboration for the pre-clinical and clinical development of the novel Cell Pouch(TM)/upcyte® combination product for the treatment of haemophilia A. The parties intend to complete negotiations of a definitive agreement while initial research is being carried out under the terms of the MTA.

"The joint development program with Medicyte is further indication that our Cell Pouch(TM) technology is versatile and has high potential to be employed for the treatment of a range of chronic diseases," said Dr. Philip Toleikis, President and CEO Sernova Corp. "We are in line with our strategy to expand the testing of the Cell Pouch(TM) in various indications by collaborating with leading cell-based therapy companies, such as Medicyte."

Dr. Joris Braspenning, CEO of Medicyte, added, "There is a great unmet medical need for the treatment of severe haemophilia A. We believe that Medicyte's upcyte® cells being sheltered in Sernova's Cell Pouch(TM) represent a promising combination of technologies to produce effective levels of Factor VIII, and to prevent excessive bleeding episodes of patients suffering haemophilia A. Together with Sernova, we are looking forward to evaluating the potential of a combined product."

Haemophilia A is the most common form of haemophilia and results from a deficiency of clotting Factor VIII to a level of less than 1% of the normal blood concentration. Haemophiliacs have prolonged bleeding which in areas such as the brain can be fatal or inside joints can be permanently debilitating. Approximately 20,000 people in the United States have the moderate or severe form of haemophilia A, as well as approximately 2,500 in Canada and 10,000 in Europe. Though there is no cure for haemophilia A, it is currently controlled with regular injections of recombinant clotting Factor VIII. Annual costs for the treatment of the disease may range from $60,000 to $260,000 per patient for a total cost of between $2-4B per year in North America and Europe.

Development of a product capable of producing an effective level of Factor VIII within the Cell Pouch(TM) environment has the potential to provide haemophilia A patients with better protection against dangerous episodes of excessive bleeding and greatly reduce annual therapy costs.

Continuation of the parties' joint studies beyond the MTA is subject to negotiation and execution of a definitive collaboration agreement.

About Medicyte

Medicyte is specialised in the controlled generation and standardisation of human primary cell products in virtually unlimited quantities and of highest quality for cell therapy and cell-based R&D. Medicyte's proprietary technologies upcyte® and vericyte® enable researchers to expand human cells from different donors and from multiple tissues in a standardized procedure, thereby making these cells for the first time commercially available in high numbers and consistent quality. Beside their therapeutic applications, pharmaceutical companies are using upcyte® and vericyte® products for in vitro assays and ADMET testing.

For further information contact: Joris Braspenning, Ph.D., CEO Tel: +49 (6221) 72925-30 j.braspenning@medicyte.com www.medicyte.com

About Sernova Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies for diseases such as parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch(TM) for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti-rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 03, 2013 3 September, 2013

Sernova to Present at 15th Annual Rodman & Renshaw Global Investment Conference


LONDON, ONTARIO (Marketwire -- Sept. 4, 2013) - Sernova Corp. (TSX-V: SVA), today announced that Dr. Philip Toleikis, Sernova's President and CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at 12:30 p.m. EDT, Tuesday, Sept. 10, in room 7.03 at the Millennium Broadway Hotel in New York City.

Dr. Toleikis will provide an overview of the company's business strategy and the ongoing Phase I/II clinical study of the Cell Pouch(TM) with insulin producing islets in patients with Type-1 diabetes.

If you are an institutional investor and interested in attending Sernova's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Dr. Toleikis.

About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable medical device which has been contract manufactured (ISO13485). It is placed under the skin, and forms an ideal environment rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type-1 diabetes receiving an islet transplant.

About Sernova

Sernova Corp is a clinical stage company developing medical technologies for the treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as hemophilia and other diseases to replace proteins or hormones in short supply in the body. Sernova is developing the Cell Pouch(TM), an implantable medical device which when placed under the skin forms an environment rich in tissue matrix and microvessels, ideal for placing therapeutic cells which then release proteins and/or hormones as required. The therapeutic cells are provided an immune-protected environment by Sernova's proprietary technology Sertolin(TM).

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 08, 2013 8 July, 2013

Sernova Receives Patent Allowance for Therapeutic Immune Privileged Cell Technologies


LONDON, ONTARIO (Marketwire - July 9, 2013) - Sernova Corp (TSX-V: SVA), today announced the Japan Patent Office has issued a Notice of Patent Allowance to Sernova for a patent entitled "The production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells."

When transplanted into a recipient, Sertoli cells provide an immune privileged environment for therapeutic cells without the need for anti-rejection drugs. The claims of this patent relate to Sertoli cells themselves which can release factors in the body to treat a range of chronic diseases such as diabetes, Parkinson's disease, various cancers, hemophilia B and other blood diseases.

"This patent allowance further strengthens Sernova's intellectual property position and provides Sernova with the unique ability to use cells with therapeutic capabilities that are also naturally protected from immune system attack," stated Dr. Philip Toleikis, Sernova's President and CEO. "We envision our Cell Pouch(TM) transplanted with these immune privileged Sertoli cells and releasing the correct replacement factor for the treatment of a variety of diseases, without the need for anti-rejection medications. We believe such a product would be a significant advancement in the cell-based treatment of deficiency diseases."

Sernova's medical collaborators have presented evidence at leading scientific conferences demonstrating that the Cell Pouch(TM) is a safe and effective platform for the delivery of factors such as insulin from therapeutic cells. Sernova is developing the Cell Pouch(TM) as an enabling platform to treat multiple chronic debilitating diseases with immune protected, therapeutic cells and is currently evaluating the safety and efficacy of the Cell Pouch(TM) in human clinical trials for diabetes.

About Sertoli Cells

Sertoli cells release protective factors that can provide a non-toxic, immune-protected environment potentially eliminating the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Production of therapeutic factors from the Sertoli cells would provide a means to treat disease without the concern of immune destruction of the transplanted therapeutic cells.

As part of its local immune protection Sertoli development process with therapeutic cells, Sernova is currently conducting preclinical studies to optimize Sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Sernova

Sernova Corp is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 23, 2013 23 June, 2013

Sernova Receives Patent Allowance for Therapeutic Cell Immune Protection Technology


LONDON, ONTARIO (Marketwire - June 24, 2013) - Sernova Corp. (TSX-V: SVA), today announced that the Australian Patent Office has issued a Notice of Patent Allowance to Sernova for a patent entitled "Adult sertoli cells and uses thereof".

Importantly, sertoli cells provide an immune privileged environment to protect donor therapeutic cells from immune system attack. When transplanted into Sernova's Cell Pouch(TM) with therapeutic cells, a safe, protected and efficacious environment is provided for therapeutic cells such as insulin-producing islets for the treatment of diabetes. The allowance of this patent will provide Sernova with patent protection through 2027 and similar patent applications have been filed in multiple countries around the world.

"The patent allowance strengthens Sernova's broad patent portfolio related to immune protection of therapeutic cells," stated Dr. Philip Toleikis, Sernova's President and CEO. "We believe the Cell Pouch(TM), proven to provide an ideal non-inflammatory, biocompatible environment, rich in matrix and microvessels for therapeutic cells, combined with sertoli local immune protection, provides the best combination of cell-based technologies to treat chronic diseases without the need for continuous anti- rejection drugs." Toleikis continued, "This strengthened patent portfolio has enabled us to expand our partnering and development opportunities as we continue to advance our Cell Pouch System(TM)."

Sernova has presented evidence at leading scientific conferences demonstrating that the Cell Pouch(TM) can be used as a safe and effective platform for the delivery of insulin from both autograft (self) and allograft (donor) islets to restore glucose control in stringent preclinical models of diabetes using the product scaled for humans. Sernova is currently evaluating the safety and efficacy of the Cell Pouch(TM) in humans in the first study of its kind in the world at the University of Alberta with Dr. James Shapiro as the principal investigator.

As the Company progresses, Sernova plans to explore the additional utility of the Cell Pouch(TM) as an enabling platform for a range of therapeutic cell types with the potential to treat multiple chronic debilitating diseases with broad unmet medical need.

About Sertoli Cells

Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 08, 2013 8 May, 2013

Sernova Provides Corporate Update and Results of 2013 Annual General Meeting


LONDON, ONTARIO--(Marketwire — May 9, 2013) - Sernova Corp. (TSX-V: SVA), provides a corporate update on the clinical development of the Cell Pouch(tm) and projections for 2013. As well, it is pleased to announce the results of the 2013 Annual General Meeting (AGM).

Cell Pouch(TM) Corporate Update

In August 2012, Sernova initiated the enrollment of patients in a Phase I/II clinical trial in Canada to evaluate the safety (primary endpoint) and efficacy (secondary endpoint) of treating diabetes with transplantation of insulin-producing islets using its Cell Pouch(TM).

"We are continuing to enroll patients in this clinical study of Sernova's Cell Pouch(TM) and we expect to announce the first interim analysis of the data in the second half of 2013," said Dr. James Shapiro MD, Ph.D. FRCS (Eng.) FRCSC, principal investigator of the Cell Pouch(TM) study and Director of the Clinical Islet Transplantation Program at the University of Alberta.

Dr. Toleikis, President and CEO Sernova Corp added, "2013 is shaping up to be a most exciting year for Sernova. We look forward to sharing important developments while continuing our strategic plan to build Sernova into a leading technology company that will improve the health and quality of life for people with diabetes and other chronic diseases."

Sernova intends to complete the following corporate objectives in 2013: Continue the enrollment of patients into the Phase I/II study of the Cell Pouch(TM), and release interim results Develop and confirm an international clinical, regulatory and commercialization strategy for the Cell Pouch(TM) for the treatment of insulin-dependent diabetes Conduct preclinical studies of the safety and efficacy of Sernova's local immune protection technology, Sertolin(TM), within the Cell Pouch(TM) through the recently announced NRC-IRAP contribution agreement Initiate preclinical, safety and efficacy studies using stem cells or xenogeneic cells within the Cell Pouch(TM) which could eventually enable treatment of a much larger number of patients with diabetes than donor islets could provide alone Establish a corporate partnership to begin development of a new product indication for the Cell Pouch(TM) Prepare regulatory documentation for initiation of a second clinical indication for the Cell Pouch(TM)

Results of Sernova's 2013 AGM

Dr. George Adams (Chair), Jeffrey Bacha, James Parsons, Bruce Weber and Dr. Philip Toleikis, were elected as the directors of the Company to hold office until the next annual general meeting of shareholders.

Davidson & Company, Chartered Accountants, was appointed auditor of the Company until the close of the next annual general meeting of shareholders, at a remuneration to be fixed by the Directors.

About Sernova

Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies such as for parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch(TM) for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti- rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 24, 2013 24 March, 2013

Sernova Awarded Funding to Optimize its Sertolin™ Local Therapeutic Cell Anti-Rejection Technology for the Treatment of Chronic Diseases


LONDON, ONTARIO (Marketwire -- March 25, 2013) -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) a clinical stage company today announced that it has been awarded a third non- refundable financial contribution of up to $254,000 from the National Research Council of Canada (NRC) Industrial Research Assistance Program (IRAP) for the optimization of its Sertolin(TM) technology within its Cell Pouch(TM) for the treatment of chronic diseases. This award brings the total contribution of IRAP to Sernova's Research and Development programs of over $1.0M since July 2009.

Sernova's proprietary Sertolin(TM) technology protects therapeutic cell types, such as insulin producing islets from immune system attack locally within the Cell Pouch(TM). Sernova believes its Sertolin(TM) technology has the potential to reduce or eliminate the need for expensive lifelong daily antirejection drug cocktails that make subjects susceptible to serious infections.

The new IRAP financial contribution is being used for a key series of studies to optimize the long-term safety and efficacy of Sertolin(TM) with insulin-producing islets in the Cell Pouch(TM). Data derived from this research will be used in a regulatory package for potential future testing in human clinical trials.

"We are quite pleased to receive NRC-IRAP support once again," said Dr. Philip Toleikis President and CEO of Sernova. "The optimization work is in line with our company's business strategy in advancing Sernova's local immune protection technology and is an important step in bringing the possibility of safe, efficacious and cost- effective cell replacement one step closer to millions of patients with chronic debilitating diseases such as diabetes."

"Sernova is unique in having the only proprietary human scalable technology solution for therapeutic cells (i.e. donor cells, stem cells, and xenogeneic cells) which can thrive within its Cell Pouch(TM) in a natural tissue matrix rich in blood vessels and protected by Sertolin(TM) from immune system attack," added Toleikis.

The successful commercialization of Sernova's Cell Pouch System(TM) with local immune protection of therapeutic cells is expected to build a substantial source of revenue for Sernova while providing an important treatment option to improve the outcome and quality of life of patients suffering from chronic diseases.

About Sertolin(TM)

Sertolin(TM) provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets by producing factors which modulate the local immune response. Sertolin(TM) may reduce or eliminate the need for immunosuppressant agents.

About The Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary medical device that, following subcutaneous implantation, incorporates with tissue and microvessels forming a natural environment for transplantation of therapeutic cells. Multiple preclinical studies demonstrated that the Cell Pouch(TM) provides a safe environment for transplanted cells, and fosters the long-term efficacy of these therapeutic cells. The Cell Pouch(TM) is currently being tested in a human clinical trial in subjects with diabetes receiving an islet transplant.

About Sernova

Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is developing a platform technology based on the Cell Pouch(TM), Sertolin(TM) and therapeutic cells, for a number of chronic diseases, including insulin-dependent diabetes as a first indication and other cell therapies such as for parathyroid disease, haemophilia, and Parkinson's disease. Sernova's goals for the Cell Pouch(TM) for diabetes include increasing the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for sources of unlimited insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti- rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 28, 2013 28 February, 2013

Sernova and Centre for Commercialization of Regenerative Medicine Partner To Treat Chronic Diseases


February 28, 2013 (TORONTO and LONDON, ON) -- The Centre for Commercialization of Regenerative Medicine (CCRM) is pleased to announce the addition of Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) to its member-based industry consortium. Sernova's combination of immuno-protective technology and therapeutic cells for the treatment of chronic diseases advances CCRM's goal of developing innovative cell- based product.

"Sernova's technology for transplanting therapeutic cells into an implanted medical device for the treatment of diabetes and other chronic diseases goes hand- in-hand with our strategy of translating cell-based medical discoveries into commercial products and therapies," says Dr. Michael May, CEO of CCRM. "Sernova's expertise in the area of cell therapy will bring great value to CCRM's core development platforms and to other consortium members."

CCRM is working with its industry consortium to address real-life bottlenecks in cell-based product pipelines. Its industry consortium now numbers over 20 members. These companies represent the key sectors of the industry: therapeutics, devices, reagents, and cells as tools.

"Becoming a member of CCRM offers the opportunity for further validation for our technology and demonstrates our company's commitment to the advancement of our Cell Pouch System(tm) as an effective, safe, long- term and convenient therapeutic option for the treatment of chronic diseases," says Dr. Philip Toleikis, President and CEO of Sernova Corp. "We will work together with the other consortium members to achieve CCRM's objectives in treating and managing devastating diseases such as diabetes."

CCRM has built three core development platforms: cell reprogramming and engineering; cell manufacturing; and, biomaterials and devices to carry out projects commissioned by academia and industry. CCRM has a fully resourced, 6,000 square foot development facility where all development work takes place.

Please visit www.ccrm.ca/industry-consortium to see a complete list of CCRM's members.

About the Centre for Commercialization of Regenerative Medicine (CCRM) CCRM, a Canadian not-for-profit organization funded by the Government of Canada's Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials- based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011.

About Sernova Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System(TM) for transplantation and long- term survival of therapeutic cells and its patented Sertolin(TM) cell technology, which can provide an immune-protected local environment for therapeutic cells.

For more information on CCRM, please contact: Stacey Johnson Manager, Communications Centre for Commercialization of Regenerative Medicine 647-309-1830 stacey.johnson@ccrm.ca www.ccrm.ca

For further information on Sernova, please contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 19, 2013 19 February, 2013

Sernova Completes Non-Brokered Private Placement


LONDON, ONTARIO - February 19, 2013 - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA) today announce that further to its news release dated January 21, 2013, it has now closed its non- brokered private placement consisting of 10,000,000 units (the "Units") at a price of $0.20 per Unit for gross proceeds of $2,000,000 (the "Offering").

Net proceeds from the offering will be utilized in the advancement of Sernova's clinical development program of its Cell Pouch(TM) for the treatment of diabetes, new product initiatives and general corporate purposes.

Each Unit consists of one common share and one common share purchase warrant (a "Warrant"), with each Warrant entitling the holder thereof to purchase one common share of the Company (a "Warrant Share") for a period of 36 months from the closing of the Offering (the "Exercise Period") at a price of $0.35 per Warrant Share for the first 24 months of the Exercise Period and at a price of $0.40 per Warrant Share for the last 12 months of the Exercise Period.

In connection with closing of the Offering, the Company paid an eligible finder a cash commission of $140,000 and issued 700,000 non-transferable finder's warrants (the "Finder's Warrants"). Each Finder's Warrant entitles the holder to purchase one common share of the Company at a price of $0.20 for a period of 24 months from the date of issuance.

All securities issued pursuant to the Offering are subject to a four month hold period expiring on June 15, 2013.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM), a medical device for transplantation and long-term efficacy of therapeutic cells and its patented Sertolin(TM) cell technology which provides local immune protection of therapeutic cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 21, 2013 21 January, 2013

Sernova Announces Non-Brokered Private Placement


LONDON, ONTARIO -- January 21, 2013 -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA) has arranged a non-brokered private placement in the amount of CDN$2.0M (the "Offering"). The Offering will consist of 10.0M units (the "Units") each sold at price of $0.20 per Unit.

"This private placement is a further indication of increased investor interest in our technology and the potential of the Cell Pouch System(TM)," said Dr. Philip Toleikis, President and CEO of Sernova Corp. "Net proceeds from the Offering will be used to fund Sernova's research studies utilizing our platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes."

Each Unit will consist of one common share and one common share purchase warrant (a "Warrant"), with each Warrant entitling the holder thereof to purchase one common share of the Company (a "Warrant Share") for a period of 36 months from the closing of the Offering (the "Exercise Period") at a price of $0.35 per Warrant Share for the first 24 months of the Exercise Period and at a price of $0.40 per Warrant Share for the last 12 months of the Exercise Period.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities law legislation. The Company may pay a finder's fee on the Offering of 7% in cash, warrants, or a combination thereof.

The Offering is subject to a number of conditions including receipt of all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the Cell Pouch System(TM), a medical device for transplantation and long-term support of therapeutic cells and its patented Sertolin(TM) cell technology which provides local immune protection of therapeutic cells.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the Shares in the United States. The Shares have not been and will not be registered under the U.S. Securities Act of 1933 or any state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act of 1933 and all applicable state securities laws, or an applicable exemption from registration requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.